QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: An approach based on behavioral and biochemical investigations

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 611-618

  Kurhe, Yeshwant ^a   Mahesh, Radhakrishnan ^a   Gupta, Deepali ^a   Devadoss, Thangaraj ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 receptor antagonist; Depression; Insulin resistance; Obesity; Plasma glucose

Indexed keywords

3 METHOXY N 4 TOLYLQUINOXALIN 2 CARBOXAMIDE; CHOLESTEROL; ESCITALOPRAM; GLUCOSE; PROTEIN; SEROTONIN 3 ANTAGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 3-METHOXY-N-P-TOLYLQUINOXALIN-2-CARBOXAMIDE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PLASMA PROTEIN; QUINOXALINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CHRONIC STRESS; CHRONIC UNPREDICTABLE MILD STRESS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; GLUCOSE BLOOD LEVEL; IMMOBILITY; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; RODENT MODEL; TAIL SUSPENSION TEST; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANALYSIS; ANIMAL; BLOOD; COMPLICATION; DRUG EFFECTS; LIPID DIET; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BLOOD PROTEINS; CHOLESTEROL; DEPRESSION; DIET, HIGH-FAT; HYPOGLYCEMIC AGENTS; MALE; MICE; MOTOR ACTIVITY; OBESITY; QUINOXALINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; STRESS, PSYCHOLOGICAL; TRIGLYCERIDES;

EID: 84919430061     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.020     Document Type: Article

References (69)

1. D.B. Allison, K.R. Fontaine, J.E. Manson, J. Stevens, and T.B. VanItallie Annual deaths attributable to obesity in the United States J. Am. Medi. Assoc. 282 1999 1530 1538
2. O.P. Almeida, J. Calver, K. Jamrozik, G.J. Hankey, and L. Flicker Obesity and metabolic syndrome increases the risk of incident depression in older men: the health in men study Am. J.Geriatr. Psychiatry 17 2009 889 898
3. S.R. Anderson, D.A. Gilge, A.L. Steiber, and S.F. Previs Diet-induced obesity alters protein synthesis: tissue-specific effects in fasted versus fed mice Metabolism 57 2008 347 354
4. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
5. P. Bjorntorp Do stress reactions cause abdominal obesity and comorbidities Obes. Rev. 2 2001 73 86
6. P. Bjorntorp, and R. Rosmond Obesity and cortisol Nutrition 16 2000 924 936
7. C.O. Bondi, G. Rodriguez, G.G. Gould, A. Frazer, and D.A. Morilak Chronic unpredictable stress induces a cognitive de.cit and anxiety like behavior in rats that is prevented by chronic antidepressant drug treatment Neuropsychopharmacology 33 2008 320 331
8. E.S. Brown, F.P. Varghese, and B.S. McEwen Association of depression with medical illness: does cortisol play a role? Bio. Psychiatry 55 2004 1 9
9. G. Buccolo, and H. David Quantitative determination of serum triglycerides by use of enzymes Clin. Chem. 19 1973 476 482
10. R. Buettner, J. Scholmerich, and L.C. Bollheimer High-fat diets: modeling the metabolic disorders of human obesity in rodents Obesity (Silver Spring) 15 2007 798 808
11. 3 receptors Horm. Metab. Res. 37 2005 482 488
12. P.C. Casarotto, and R. Andreatini Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone Eur. Neuropsychopharmacol. 17 2007 735 742
13. J.F. Cryan, and D.A. Slattery Animal models of mood disorders: recent developments Curr. Opin. Psychiatry 20 2007 1 7
14. J.F Cryan, and A. Holmes The ascent of mouse: advances in modeling human depression and anxiety Nat. Rev. Drug Discov. 4 2005 775 790
15. 3B subunit is a major determinant of serotonin receptor function Nature 397 1999 359 363
16. G.R. Dawson, and M.D. Tricklebank Use of the elevated plus-maze in the search for novel anxiolytic agents Trends Pharmacol. Sci. 16 1995 33 36
17. K.S. Dobson An analysis of anxiety and depression scales J. Pers. Assess. 49 1985 522 527
18. C. Ducottet, G. Griebel, and C. Belzung Effects of the selective nonpeptide corticotrophin releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 625 631
19. B. Eisensamer, G. Rammes, G. Gimpl, M. Shapa, U. Ferrari, G. Hapfelmeier, and R. Rupprecht Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor Mol. Psychiatry 8 2003 994 1007
20. C.G. Engeland, K. Martin, and O. Klaus-Peter Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats Pharmacol. Biochem. Behav. 74 2003 433 447
21. A.N. Fabricatore, and T.A. Wadden Psychological aspects of obesity Clin. Dermatol. 22 2004 332 337
22. M.H. Gaiva, R.C. Couto, L.M. Oyama, G.E. Couto, V.L. Silveira, E.B. Riberio, and C.M. Nascimento Polyunsaturated fatty acid-rich diets: effect on adipose tissue metabolism in rats Br. J. Nutr. 86 2001 371 377
23. I.H. Gotlib Depression and general psychopathology in university students J. Abnorm. Psychol. 93 1984 19 30
24. E. Haroon, C.L. Raison, and A.H. Miller Psychoneuroimmunology meets neuropsycho- pharmacology: translational implications of the impact of inflammation on behavior Neuropsychopharmacology 37 2012 137 162
25. 3 receptor channel system for insulin secretion and interaction of ginger extracts Eur. J. Pharmacol. 624 2009 58 65
26. J. Herrstedt, and P. Dombernowsky Anti-emetic therapy in cancer chemotherapy: current status Basic Clin. Pharmacol. Toxicol. 101 2007 143 150
27. S. Hogg A review of the validity and variability of the elevated plus maze as an animal model of anxiety Pharmacol. Biochem. Behav. 54 1996 21 30
28. J. Horacek, M. Kuzmiakova, C. Hoschl, M. Andel, and R. Bahbonh The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers Psychoneuroendocrinology 24 1999 785 797
29. 3) Antagonists Curr. Med. Chem. - CNS Agents 1 2001 171 199
30. B.B. Kahn, and J.S. Flier Obesity and insulin resistance J. Clin. Invest. 106 2000 473 481
31. G. Klerman, and M.M. Weismann The course, morbidity, and cost of depression Arch. Gen. Psychiatry 49 1992 831 834
32. A. Koller Total serum protein LA Kaplan, AJ Pesce, Clinical chemistry, theory, analysis, and correlation 1984 Mosby Company St. Louis 316 319
33. 3 receptor antagonist 3-methoxy-n-p-tolylquinoxalin-2-carboxamide (QCM-4) on the acute and chronic rodent models of depression. Int J. Pharm. Pharmacol. 5 2013 567 573
34. 3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice J. Pharm. Pharmacol. 66 2014 122 132
35. Y.S. Lee, B.Y. Cha, S.S. Choi, B.K. Choi, T. Yonezawa, T. Teruya, and J.T. Woo Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice J. Nutr. Biochem. 24 2013 156 162
36. F.S. Luppino, L.M. de Wit, P.F. Bouvy, T. Stijnen, P. Cuijpers, B.W. Penninx, and F.G. Zitman Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies Arch. Gen. Psychiatry 67 2010 220 229
37. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med. 3 2006 e442
38. M. Maes, A. Wauters, H. Neels, S. Scharpé, A. Van Gastel, P. D'Hondt, and R. Desnyder Total serum protein and serum protein fractions in depression: relationships to depressive symptoms and glucocorticoid activity J. Affect. Disord. 34 1995 61 69
39. S.A. Mark, J.T. Arnedt, S. Leisha, S. Jaime, S. Michael, and P.M. Richard Examining the construct of depression in obstructive sleep apnea syndrome Sleep Med. 6 2005 115 121
40. S. Markowitz, M.A. Friedman, and S.M. Arent Understanding the relation between obesity and depression: causal mechanisms and implications for treatment Clin. Psychol.: Sci. Pract. 15 2008 1 20
41. 3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia Neuropsychopharmacology 17 1997 360 369
42. F. Meittini, F. Prencipe, G. Bardelli, G. Giannini, and P. Tarli The 4-hydroxybenzoate/4-aminophenazone Chromogenic Syst. Clin. Chem. 24 1978 2161 2165
43. M.C. Moore, C.A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, D.W. Neal, and A.D. Cherrington Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs Am. J. Physiol. Endocrinol. Metab. 287 2004 E1057 E1063
44. M.C. Moore, W.B. Geho, M. Lautz, B. Farmer, D.W. Neal, and A.D. Cherrington Portal serotonin infusion and glucose disposal in conscious dogs Diabetes 53 2004 14 20
45. M.C. Moore, C.A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, and A.D. Cherrington Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs Am. J. Physiol. Endocrinol. Metab. 288 2005 E556 E563
46. M.C. Moore, K. Kimura, H. Shibata, T. Honjoh, M. Saito, C.A. Everett, and C.A. Everett Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs Am. J. Physiol. Endocrinol. Metab. 289 2005 E225 E231
47. A. Must, J. Spadano, E.H. Coakley, A.E. Field, G. Colditz, and W.H. Dietz The disease burden associated with overweight and obesity J. Am. Med. Assoc. 282 1999 1523 1529
48. K. Nonogaki, and A. Iguchi Role of central neural mechanisms in the regulation of hepatic glucose metabolism Life Sci. 60 1997 797 807
49. M.J. Owens, and C.B. Nemeroff Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter Clin. Chem. 40 1994 288 295
50. B.M. Spiegelman, and J.S. Flier Obesity and the regulation of energy balance Cell 104 2001 531 543
51. R.D. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 229 1977 327 336
52. K. Raikkonen, L. Keltikangas-Jarvinen, H. Adlercreutz, and A. Hautanen Psychosocial stress and the insulin resistance syndrome Metab. Clin. Exp. 45 1996 1533 1538
53. R. Ramamoorthy, R. Radhakrishnan, and M. Borah Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models Behav. Pharmacol. 19 2008 29 40
54. 3 receptors in depression: a probable neuronal target J. Psychopharmacol. 24 2010 455 569
55. R.J. Rodgers, and A. Dalvi Anxiety, defence and the elevated plus-maze Neurosci. Biobehav. Rev. 21 1997 801 810
56. N.L. Rosgan, M.S. Carter, S. Elman, M. Bauer, M. Love, and S.G. Korenman Common treatment of polysystic ovary syndrome and major depressive disorder: case study and review Curr. Drug Targets Immune Endocr. Metabol. Disord. 2 2002 91 102
57. R.G. Ruddell, D.A. Mann, and G.A. Ramm The function of serotonin within the liver J. Hepatol. 48 2008 666 675
58. S. Sharma, and S. Fulton Diet-induced obesity promotes depressive-like behavior that is associated with neural adaptations in brain reward circuitry Int. J. Obes. 37 2012 382 389
59. K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, and P. Ramarao Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol. Res. 52 2005 313 320
60. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice J. Psychopharmacol. 85 1985 367 370
61. 3 receptor in rat brain using radioligand binding Proc. Natl. Acad. Sci. USA 90 1993 1430 1443
62. P. Trinder Enzymatic method of glucose estimation Ann. Clin. Biochem. 6 1969 24 33
63. A.K.B. van Reedt Dortland, E.J. Giltay, T. van Veen, J. van Pelt, and F.J. Zitman Association between serum lipids and Major depressive disorder: results from Netherlands Study of Depression and Anxiety (NESDA) J. Clin. Psychiatry 71 2010 729 736
64. S.C. Wagner, D.S. Daniel, M.M. Monica, and S. Mauro Serotonin modulates hepatic 6-phosphofructo-1-kinase in an insulin synergistic Manner Int. J. Biochem. Cell. Biol. 44 2012 150 157
65. P. Willner Chronic mild stress (CMS) revisited: consistency and behavioral-neurobiological concordance in the effects of CMS Neuropsychobiol 52 2005 90 110
66. P. Willner, and P.J. Mitchell The validity of animal models of predisposition to depression Behav. Pharmacol. 13 2002 169 188
67. P. Willner, A. Towell, D. Sampson, S. Sophokleous, and R. Muscat Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant Psychopharmacology 93 1987 358 364
68. 3 receptor Antagonists Scand. J. Rheumatol. 29 2000 37 45
69. N. Yamada, G. Katsuura, Y. Ochi, K. Ebihara, T. Kusakabe, K. Hosoda, and K. Nakao Impaired CNS leptin action is implicated in depression associated with obesity Endocrinology 152 2011 2634 2643